The Epstein-Barr virus (EBV) or human herpesvirus-4, a lymphocryptovirus (LCV) species from the γ-herpesvirus subfamily, is a global human pathogen that establishes lifelong persistent infections in 90-95% of the human population. Primary lytic replication of EBV in oropharyngeal mucosal epithelium precedes a long-lived latent infection of resting memory B cells 1,2 . The dual cell tropism of EBV is the basis for the wide spectrum of pathologies associated with EBV infections, which most notably includes the lymphoproliferative disorder infectious mononucleosis 2 .
a r t i c l e s
The Epstein-Barr virus (EBV) or human herpesvirus-4, a lymphocryptovirus (LCV) species from the γ-herpesvirus subfamily, is a global human pathogen that establishes lifelong persistent infections in 90-95% of the human population. Primary lytic replication of EBV in oropharyngeal mucosal epithelium precedes a long-lived latent infection of resting memory B cells 1, 2 . The dual cell tropism of EBV is the basis for the wide spectrum of pathologies associated with EBV infections, which most notably includes the lymphoproliferative disorder infectious mononucleosis 2 .
Like most LCVs, EBV coevolved with its host by developing sophisticated interactions with host molecular targets that mainly exploit molecular mimicry to evade detection and elimination by the human immune system 3 . A striking aspect of the EBV proteomic pool concerns the secretion of the lytic-cycle early protein BARF1 (BamHI-A rightward frame-1), which, like BCRF1 (Bam HI-C rightward frame-1, also known as vIL-10), is a product of a pool of transcripts that occur only in LCV infection in higher primates 4 . Expression and secretion of BARF1 is highly associated with epithelial malignancies, including nasopharyngeal carcinoma and gastric carcinoma 5, 6 , and elicits a strong humoral immune response 7 . Furthermore, BARF1 emerged as a potential oncoprotein because of its transforming and mitogenic behavior in murine fibroblasts, human B cells and monkey epithelial cells [8] [9] [10] [11] [12] . However, a controversial role of BARF1 in the transformation of naive human B cells has recently been described 13, 14 .
The discovery that BARF1 is a binding protein for the hematopoietic cytokine hCSF-1, a central cytokine in innate and adaptive immunity in humans, established a link to the possible immunomodulatory role of BARF1 (ref. 15) . BARF1 was also shown to inhibit the secretion of antiviral interferon (IFN)-α (ref. 13) , which, interestingly, is produced by mononuclear cells, as a result of hCSF-1 activity 16 . Together with IFN-γ, IFN-α establishes a primary response via CD8 + cytotoxic T-cells and natural killer cells to clear EBV-infected cells 17 , in line with T cell-mediated adaptive immunity against EBV 18 . hCSF-1 initiates intracellular signaling pathways by activating its cognate receptor, hCSF-1R, a cell-surface class III receptor tyrosine kinase (RTK-III), leading to the proliferation, differentiation and activation of cells derived from the mononuclear phagocytic lineage 19 . Bivalent binding of dimeric hCSF-1 to extracellular immunoglobulin-like domains 2 and 3 of hCSF-1R dimerizes the receptor to prime homotypic receptor-receptor interactions that help establish a cooperative high-affinity complex 20 .
We here present the structural and mechanistic basis of the inactivation of hCSF-1 signaling by BARF1 to achieve immunomodulation. Our studies have exposed a new paradigm for virus-human protein interactions and have deepened our understanding of the molecular and structural determinants of the hCSF-1-hCSF-1R extracellular signaling assembly and its potential targeting for therapeutic purposes.
the momentum transfer, indicating large deviations in shape (Fig. 1d and Supplementary Table 1) . Starting with the crystal structure of BARF1, the SAXS data could be fitted well (χ 2 = 1.3) by normal mode analysis (NMA) 22 based on an iterative structure-refinement protocol employing linear combinations of two normal modes in each step. The refined model displays a squashed ring structure (Fig. 1d) that contrasts the symmetric toroid of BARF1 in crystal structures of both its unliganded form 21 and complex with hCSF-1 (Fig. 1a) . Thus unbound BARF1 may display some flexibility manifested as alternative conformations, a notion further supported by the increase in D max and features of the distance distribution function (Fig. 1d) .
The BARF1-hCSF-1 interaction site
The structural trivalency of the BARF1-hCSF-1 complex is accompanied by numerous unexpected findings concerning the strategy adopted by BARF1 to sequester hCSF-1. BARF1 employs the β-turn between strands D and E and the BC loop of its N-terminal immunoglobulin-like domain to create the tandem tips of a structural 'tweezer' that grabs dimeric hCSF-1 at the meeting point of the two head-to-head antiparallel β-sheets at the hCSF-1 dimer interface, staying clear of the helical-bundle core of hCSF-1 (Fig. 2a,b) . Whereas the two-fold axis of the composite BARF1 binding interface coincides with that of the hCSF-1 dimer, each arm of the tweezers contacts the hCSF-1 dimer asymmetrically, burying ~560 Å 2 of surface area on one hCSF-1 subunit and ~300 Å 2 on the other (Fig. 2a) .
Unexpectedly, we found that the BARF1-hCSF-1 interaction site is sterically distinct from the canonical binding site employed by hCSF-1 when binding to its cognate receptor hCSF-1R 20 . Superposition of the molecular envelope of the hCSF-1-hCSF-1R complex, as determined by EM 20 (EMDB access code EMD-1977) with the BARF1-hCSF-1 npg a r t i c l e s complex, using bound hCSF-1 as a reference shows that a supercomplex can be readily constructed (Fig. 2b) . Furthermore, BARF1 establishes two limited and tight clusters of interactions with hCSF-1: those arising from the DE β-turn comprising residues 82-86, and those mediated by the BC loop defined by residues 34-39 ( Fig. 2c and Supplementary  Table 2) . Notably, BARF1 does not interact with any key residue on hCSF-1 participating in the canonical binding site with cognate hCSF-1R 20, 23 .
The DE β-turn exclusively contributes side chains to the BARF1-hCSF-1 interaction site. The most elaborate interaction is mediated by Asn85, which establishes bifurcated hydrogen bonds with the main chain oxygen and nitrogen of Thr34 in hCSF-1 (Fig. 2c) . The Asn85 side chain orientation is defined by a hydrogen bond with the main chain oxygen of Trp35. The BC loop structure establishes a more varied set of interactions with hCSF-1 ( Fig. 2c and Supplementary Table 2 ). In particular, we highlight Val38, which inserts into the hCSF-1 dimer interface to make contacts with Ile33 and the aliphatic parts of Thr64 and Thr29′. The prime symbol refers to amino acid residues in the second subunit of the hCSF1 dimer. Moreover, the main chain nitrogen of Val38 donates a hydrogen bond to the carbonyl oxygen of Asp63 in hCSF-1, whereas its own main chain oxygen is hydrogenbonded to the main chain nitrogen and side chain of Ser30′ in hCSF-1 (Fig. 2c) . Thus, Val38 mediates an interaction bridge between both hCSF-1 subunits. In addition, the main chain nitrogen atoms of the Val38-Leu40-Gly41 stretch participate in an intricate hydrogenbonding network with Ser30′ in hCSF-1. Finally, we note that Arg36 and Arg37 in the BARF1 BC loop are structurally heterogeneous and partially disordered, as was previously observed in unbound BARF1 (ref. 21) . However, in one of the four complexes in crystal form 2, Arg37 participates in an intricate salt-bridge network with several hCSF-1 residues (Fig. 2c) .
BARF1 binds to hCSF-1 with ultrahigh affinity
Isothermal titration calorimetry (ITC) measurements obtained by titrating hCSF-1 to BARF1 revealed a strongly enthalpically driven binding event associated with the binding of three hCSF-1 dimers to BARF1 (Fig. 3a) , in agreement with our structural observations (Fig. 1) . However, the titration transition in the resultant binding isotherm was too steep to allow an accurate calculation of the equilibrium dissociation constant, K D , suggesting an affinity well into the subnanomolar range (Fig. 3a) . Using displacement ITC 24 , we titrated BARF1 into an established hCSF-1R D1-D5 -hCSF-1 complex, leading to a K D = 2.50 pM (K D,app = 1.96 nM) ( Fig. 3b and Supplementary  Table 3) , which is at least one order of magnitude tighter than for the interaction of hCSF-1 with cognate hCSF-1R in vivo 25 .
Kinetic characterization of the BARF1-hCSF-1 interaction by surface plasmon resonance (SPR) led to a moderately fast k on coupled to a very slow k off dissociation rate constant (Fig. 3c) , the latter indicating a mean lifetime of at least 24 h for the BARF1-hCSF-1 complex. Together, such binding characteristics can be compared with some of the tightest cytokine-receptor interactions measured to date 26 , and they show that BARF1 harbors the traits of a very effective sequestration platform for hCSF-1.
In light of the compact structural footprint of the BARF1-hCSF-1 interaction, we sought to delineate the relative contribution of the DE β-turn and BC loop in BARF1. Five amino acids from the BC loop were mutated to alanine, and the thermodynamic binding fingerprint of the mutant was characterized by ITC. This revealed a decrease in the affinity of the complex by a factor of 10 4 ( Supplementary Fig. 2a a r t i c l e s and Supplementary Table 3 ). To our surprise, mutating residues Arg82, Ser83, Asn85 and Thr86 from the DE β-turn, which contributes only side chain interactions to the binding site, to alanine had virtually no effect on the thermodynamics of the interaction (Supplementary Fig. 2a and Supplementary  Table 3 ). Thus, the BC loop main chain contacts mediated by Val38, Ser39, Leu40 and Gly41 appear to provide most of the binding energy for the nanomolar affinity between the BC-loop mutant variant and hCSF-1. The BC loop side chain interactions then likely contribute another 3.4 kcal mol −1 (four orders of magnitude gain in affinity) to reach the low picomolar affinity of the BARF1-hCSF-1 complex. This corollary also agrees well with the preservation of the BC loop and DE β-turn conformations in unbound BARF1. The importance of the BC loop and DE β-turn is further illustrated by the strict conservation of the two corresponding sequences in rhesus LCV BARF1 (BARF1 rhLCV ) ( Fig. 2c) , which shares an overall 75% sequence identity with BARF1. Indeed, the BARF1 rhLCV -hCSF-1 interaction reveals a nearly identical binding fingerprint as for the canonical BARF1-hCSF-1 complex ( Supplementary Fig. 2b and Fig. 3a ).
To gain further insights into the apparent lack of steric overlap between the BARF1-binding site on hCSF-1 and the cognate receptorbinding site, we employed a previously reported quadruple point mutant of hCSF-1 carrying mutations in two discrete interaction patches crucial for hCSF-1R binding (H9A H15A and Q58A D59A) 23, 27 . Binding studies by ITC show that this quadruple point mutant of hCSF-1 has a nearly identical thermodynamic profile to wild-type hCSF-1 ( Supplementary Fig. 2c ), further supporting the steric distinctness of the BARF1-hCSF-1 binding site.
BARF1 is an allosteric decoy receptor for hCSF-1
It has been unclear whether BARF1 is a decoy receptor of hCSF-1 or rather a co-stimulatory molecule 13, 15 . A role as decoy receptor is seemingly incompatible with the distinct BARF1 binding site on hCSF-1 (Fig. 2b) . On the other hand, the picomolar affinity for the BARF1-hCSF-1 interaction reported here is typical for decoy receptors 28 .
To investigate the postulated agonistic or antagonistic role of BARF1, we sought to exploit the very slow dissociation kinetics of the BARF1-hCSF-1 interaction (Fig. 3c) in an ITC experiment, whereby purified BARF1-hCSF-1 was titrated with the full-length ectodomain of hCSF-1R (hCSF-1R D1-D5 ). The titration reveals that when hCSF-1 is bound by BARF1, it is unable to interact with its cognate receptor ( Fig. 4a) , sharply contrasting with the high-affinity interaction revealed in control titrations of hCSF-1R D1-D5 against hCSF-1 (K D = 92 nM) (Supplementary Fig. 3a ) and vice versa 20 . This result further validates our quantification of the BARF1-hCSF-1 interaction by displacement ITC (Fig. 3b) .
We further wondered whether the apparent combined neutralization and inactivation of hCSF-1 by BARF1 could be reflected in a comparative cellular assay that would investigate stimulation of purified CD14 + monocytes from human peripheral blood mononuclear cells (PBMCs) as a function of three molecular species: hCSF-1, BARF1 and purified BARF1-hCSF-1 complex. Western blot analysis of hCSF-1R activation, as traced via trans-phosphorylation of Tyr723 (pTyr723) on hCSF-1R and of cellular hCSF-1R, revealed that the BARF1-hCSF-1 complex is unable to signal via hCSF-1R (Fig. 4b) . This contrasts sharply with normal hCSF-1 signaling, whereby hCSF-1R shows a dose-dependent response and saturation as a function of hCSF-1 stimulation, followed by internalization and degradation (Fig. 4b) .
A follow-up cellular assay employing the CSF-1-dependent Bac1.2F5 cell line 29 showed that cell growth proceeds until BARF1 abundance exceeds a 1:3 stoichiometric ratio with hCSF-1 ( Fig. 4c and  Supplementary Fig. 3b) . Similarly, cellular proliferation is initially suppressed in the presence of a fixed amount of BARF1 and at rising concentrations of hCSF-1 until a molar excess of hCSF-1 is reached.
BARF1 blocks cooperative assembly of hCSF-1R-hCSF-1
The lack of structural overlap between the BARF1-hCSF-1 and hCSF-1R-hCSF-1 interaction sites and the ability of BARF1 to efficiently npg a r t i c l e s abrogate hCSF-1 signaling prompted us to explore a mechanistic explanation that goes beyond antagonization based on steric hindrance. A crystallographic study on a fortuitous new crystal form of hCSF-1 revealed five independent copies of hCSF-1 in the asymmetric unit of the crystal ( Table 1) . The five hCSF-1 dimers feature an intrinsic butterfly-like plasticity about their dimer interface, manifested by different tilt angles between hCSF-1 subunits about a pivot point at the top of the hCSF-1 dimer interface (Fig. 5a) . This location essentially constitutes the focal point of the BARF1-binding site. Superposition of the 13 hCSF-1 structures at our disposal-that is, the five copies of unbound hCSF-1 and the eight copies of hCSF-1 derived in the two crystal forms of the BARF1-hCSF-1 complex-establishes that BARF1 locks hCSF-1 into a single conformational species corresponding to the most collapsed state in our set of hCSF-1 structures (Fig. 5a) . Indeed, when compared to the most open state of unbound hCSF-1, the BARF1-bound state collapses by 10°. Such butterfly-like domain swings of cytokine subunits, both in extent and direction, appear to be a common structural feature among the dimeric α-helical cytokines of the RTK-III family of receptors, when involved in a ternary complex with the full-length ectodomains of their cognate receptors 30, 31 (Supplementary Fig. 4) . Furthermore, conserved dimerization-sequence fingerprints in extracellular-domain D4 have been linked to the ability of RTK-III to engage in homotypic receptor-receptor interactions 20, 30 . In the case of hCSF-1R, such receptor-receptor interactions were shown to contribute one order of magnitude to the total affinity of the extracellular assembly 20, 32 , calling for a mechanistic scenario based on positive cooperativity.
To investigate the mechanistic importance of cytokine subunit plasticity in the assembly of a cooperative complex, we tested the ability of hCSF-1R D1-D3 , which comprises the complete ligand-binding portion of CSF-1R but lacks the D4-D5 module necessary for homotypic receptor contacts, to engage in an encounter complex with hCSF-1 bound to BARF1. An ITC experiment whereby BARF1-hCSF-1 complex was titrated with hCSF-1R D1-D3 revealed a low-affinity binding (K D = 3 µM) that is about ten times weaker than the interaction of hCSF-1R D1-D3 with free hCSF-1 (ref. 20) (Fig. 5a) . Furthermore, the interaction is based on a binary complex (one hCSF-1R D1-D3 and one BARF1-bound hCSF-1) instead of a ternary complex, which would be expected from the capacity of free hCSF-1 to bivalently engage two molecules of hCSF-1R D1-D3 (ref. 20) . Therefore, this provides the first evidence to date that the inherent plasticity of the hCSF-1 dimer must be critically important for the assembly of the extracellular complex.
It would thus appear that BARF1 forces dimeric hCSF-1 to adopt a conformation that is too constrained to evoke a ternary cytokinereceptor complex yet exposed enough to form a binary encounter complex with an hCSF-1R variant lacking domains 4 and 5. Furthermore, the inability of the full-length ectodomain of hCSF-1R to engage in any kind of interaction with BARF1-bound hCSF-1 (Fig. 4a) suggests that the plasticity of the dimeric cytokine is inextricably linked to extracellular complex formation including an encounter complex and homotypic receptor contacts.
To investigate this principle further, we constructed a monomeric hCSF-1 variant (Supplementary Fig. 5a,b) and used ITC to characterize its ability to bind to hCSF-1R D1-D5 , hCSF-1R D1-D3 (Fig. 5b) and BARF1 (Supplementary Fig. 5b) . hCSF-1R D1-D5 and hCSF-1R D1-D3 both bind monomeric hCSF-1 with a stoichiometry of 1.0 to form a binary complex that is similar in affinity (K D = ~2.5 µM) to the complex of hCSF-1R D1-D3 with BARF1-bound hCSF-1 (Fig. 5a) . We note that these affinities are lower by a factor of 10 2 and 10 1 , respectively, than the canonical K D values of these ectodomain variants against dimeric hCSF-1 ( Supplementary Fig. 5c npg a r t i c l e s cooperative hCSF-1-hCSF-1R complex is nearly as much as that from receptor-receptor interactions. This also confirms the prevailing notion that dimeric hCSF-1 is needed for ternary complex formation and therefore receptor activation. At the same time, monomeric hCSF-1 is unable to bind to BARF1 (Supplementary Fig. 5b) , confirming that the hCSF-1 dimer interface is the actual target for BARF1.
Mouse CSF-1 is an unexpected ligand for BARF1
EBV infection is limited to humans and New World monkeys, yet many studies have reported a mitogenic role of BARF1 in a murine cellular background 8, 9, 11, 33 . Given the strong conservation of the BARF1 interaction site on hCSF-1 in mouse CSF-1 (mCSF-1) (Supplementary Fig. 6a ), we sought to assess the possible interaction of BARF1 with mCSF-1. Unexpectedly, the interaction of BARF1 with recombinant mCSF-1 is also characterized by a subnanomolar K D and slow dissociation kinetics ( Fig. 6a and Supplementary Fig. 6b ), which at first sight contrasts with the reported inability of BARF1 to neutralize mCSF-1 (ref. 15 ).
To investigate the structural basis of the BARF1-mCSF-1 interaction, we determined the crystal structure of the BARF1-mCSF-1 complex to 4.5-Å resolution ( Table 1) . The BARF1-mCSF-1 structure is overall very comparable to the BARF1-hCSF-1 complex (r.m.s. deviation of 0.6 Å for BARF1 Cα atoms; r.m.s. deviation of 0.8 Å Fig. 6c ). We also determined the crystal structure of unbound mCSF-1 ( Table 1 and Supplementary Fig. 6d) , to investigate the conformational plasticity of mCSF-1 upon binding to BARF1. The intersubunit tilt in unbound mCSF-1 is identical to that observed in the binary complex with mCSF-1R D1-D3 (ref. 23) (r.m.s. deviation of 0.6 Å for Cα atoms) (Supplementary Fig. 6d) , consistent with the observation that the cytokine intersubunit tilt is only featured in cytokine-RTKIII ternary complexes ( Supplementary  Fig. 4 ). In addition, unbound mCSF-1 is 5° more open than unbound hCSF-1 (Supplementary Fig. 6d ). Therefore, whereas BARF1 enforces the same type of tilt to mCSF-1 and hCSF-1 alike, mCSF-1
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BARF1 does not block signaling mediated by mCSF-1R-mCSF-1
To test whether BARF1-bound mCSF-1 could still bind to its cognate receptor, mCSF-1R, preformed BARF1-mCSF-1 complex isolated by size-exclusion chromatograpy (SEC) was titrated into mCSF-1R D1-D5 . In marked contrast to the corresponding setup involving the human counterparts (Fig. 4a) , mCSF-1 bound to BARF1 does bind to mCSF-1R D1-D5 (Fig. 6b) . The BARF1-mCSF-1-mCSF-1R D1-D5 interaction is characterized by an unusually high enthalpic component (~-90 kcal mol −1 ), which is ~40 kcal mol −1 more favorable than the enthalpic contribution measured for the cognate mCSF-1-mCSF-1R D1-D5 interaction 20 . Yet, notably, the interaction is ~200 times weaker, 4.1 µM versus 22 nM 20 , as a result of a large entropic penalty (-80 kcal mol −1 ). Furthermore, the measured stoichiometry is indicative of a mCSF-1-mCSF-1R D1-D5 ternary complex.
Taking advantage of the cross-reactivity of hCSF-1 and mCSF-1R 20 , we titrated BARF1-hCSF-1 into mCSF-1R D1-D5 in an ITC experiment and found that BARF1 abolishes binding of hCSF-1 to mCSF-1R D1-D5 (Fig. 6b) . Thus, BARF1 has evolved to mechanistically target hCSF-1 specifically and not mCSF-1. In addition, whereas the assembly principles of human and mouse CSF-1-CSF-1R complexes are similar 20 , the modularity requirements and plasticity of human and mouse CSF-1 must differ in the context of their cooperative complexes with cognate receptors. Given the low micromolar affinity for the BARF1-mCSF-1-mCSF-1R D1-D5 supercomplex, we wondered whether such assembly could be isolated by SEC. Indeed, loading the post-ITC titration mixture of BARF1-mCSF-1-mCSF-1R D1-D5 led to the isolation of the supercomplex, whereas the post-ITC titration mixture of mCSF-1R D1-D5 and BARF1-hCSF-1 yielded molecular species that eluted separately (Fig. 6c) .
In a parallel surface plasmon resonance (SPR) experiment, immobilized BARF1-mCSF-1 and BARF1-hCSF-1 complexes were allowed to interact with mCSF-1R D1-D5 . mCSF-1R D1-D5 showed significant binding to the BARF1-mCSF-1 complex (K D = 9.7 µM) (Fig. 6d) , in good agreement with the K D = 4.1 µM value obtained via ITC (Fig. 6b) . Whereas some signal could be observed for the interaction of mCSF-1R D1-D5 with the BARF1-hCSF-1 complex, the SPR sensorgrams suggest a K D for the interaction well into the millimolar range. Notably, the interaction of mCSF-1R D1-D3 and BARF1-mCSF-1 reveals a K D = 12.5 µM and is essentially indistinguishable from the interaction with the full-length ectodomain (Supplementary Fig. 7) .
To extrapolate our findings to a cellular context, we set up an assay similar to the BARF1-hCSF-1 interaction, whereby isolated mouse bone-marrow cells containing progenitors expressing mCSF-1R were stimulated with either mCSF-1, BARF1 or the BARF1-mCSF-1 complex. Stimulation with BARF1-mCSF-1 complex led to strong activation of mCSF-1R, as evidenced by the native-like phosphorylation status of Tyr721 and Tyr807 of mCSF-1R (Fig. 7a) , in stark contrast to our cellular assays investigating activation of hCSF-1R in the context of the BARF1-hCSF-1 complex (Fig. 4b) . In addition, mCSF-1-driven proliferation in Bac1.2F5 cells could not be antagonized in the presence of BARF1 (Fig. 7b and Supplementary Fig. 3b) .
Together, our data show that the low micromolar affinity measured for BARF1-bound mCSF-1 for its cognate mCSF-1R ectodomain in vitro is likely improved by three orders of magnitude in a cellular context involving full-length receptor, as was already observed for several RTK-III complexes 20, 31, 32, 34 . Thus, the interaction of mCSF-1R with mCSF-1 in the context of a BARF1-mCSF-1 complex is strong enough to stimulate cellular proliferation, and, depending on the internalization kinetics of the BARF1-mCSF-1-mCSF-1R supercomplexes, it may lead to overstimulation and tumorigenic transformation, in line with previous work in mouse model systems.
DISCUSSION
Two decades after the discovery that EBV secretes the immunomodulatory protein BARF1 and the subsequent emergence of BARF1 as an omnipresent viral protein in EBV-associated malignancies, we present the molecular and structural basis of sequestration and inactivation of the essential human hematopoietic cytokine hCSF-1 by the secreted decoy receptor BARF1. Prior to our study, diverse studies on the structural basis of immune subversion by immune modulators encoded by large DNA viruses [35] [36] [37] [38] [39] had established that molecular mimicry 3 , whereby the viral molecule resembles its human counterpart structurally and functionally, lies at the heart of such virushuman protein complexes.
Perhaps the most far-reaching dimension of our work is the uncovering of a unique mechanism for the inactivation of a human growth factor by a viral decoy receptor to achieve immunomodulation. BARF1 is structurally different from the cognate receptor for hCSF-1, and it evolved to target a novel binding site at the dimer interface of hCSF-1, distinct from the cognate receptor-binding site. Via this binding strategy, BARF1 forces hCSF-1 to adopt a conformational state that renders the cytokine unable to establish a ternary complex with its cognate receptor, thereby abrogating signaling. Thus, not only is BARF1 an exquisitely efficient decoy receptor, albeit a nonclassical one, it is essentially an allosteric competitive antagonist as well. This unprecedented (to our knowledge) mechanistic conclusion provides a substantive advancement in our understanding of the possible molecular mechanisms deployed by pathogens in evading and subverting key host signaling pathways. Importantly, it frees us from the expectation that molecular mimicry and direct competition against common interaction sites should be at play. This is particularly important at a time when studies delineating the interactome landscape of major human pathogens take center stage 40, 41 .
A second mechanistic breakthrough from our studies is the discovery that the plasticity of dimeric hCSF-1 is a mechanistic prerequisite for establishing signaling-competent ternary complexes with hCSF-1R. Up until now, cooperative assembly of the hCSF-1-hCSF-1R ternary complex was thought to proceed as a result of receptor-receptor interactions following formation of an initial cytokine-receptor encounter complex. Not only have we now quantified the affinity of this basic encounter complex, but we have also determined that hCSF-1 dimer plasticity contributes one order of magnitude to the affinity of the extracellular complex. Thus, a synthesis of experimental evidence now allows the deconvolution of the in vivo affinity of the CSF-1-CSF-1R complex 25 (~50 pM) into modular contributions stemming from an initial encounter complex, the dimer plasticity of hCSF-1, ectodomain receptor contacts 20 , TM-domain dimerization 42 and the two-dimensional spatial confinement of the membrane. In a viral context, the ubiquity of circulating hCSF-1 (ref. 43 ) and its picomolar affinity to its cognate receptor essentially necessitate the employment of a competitive decoy receptor that can establish a tight and longlived complex with hCSF-1. Furthermore, our studies indicate that an encounter complex, cytokine intersubunit plasticity and receptorreceptor contacts all are concomitant events in the cooperative mechanism of hCSF-1R activation. Such insights bring us closer to understanding the intricacies of cytokine-induced receptor activation and are likely to initiate a renewed interest in mechanistic studies of other oligomeric cytokines and receptor families. npg a r t i c l e s Our studies aiming to investigate the fortuitous BARF1-mCSF-1 interaction clearly caution against the study of LCV or EBV pathogenesis and isolated BARF1 in non-native cellular backgrounds. Although mouse and human CSF-1 fulfill the same role in vivo in their cognate context, EBV exclusively infects humans and New World monkeys. Yet BARF1, like many other protein effectors, has been extensively studied in immortalized mouse cell lines such as NIH/3T3 or Balb/c3T3 (refs. 8,12,33) . These studies attributed a mitogenic and transforming activity to BARF1, results that cannot be reconciled with observations in isolated PBMC monocytes and B cells 13, 15 and rhesus macaques infected with rhesus LCV 14 . The unexpected finding that BARF1-bound mCSF-1 can potently activate mCSF-1R-keeping in mind the corollary that monocytes may be driven to transformation due to overstimulation-is likely a consequence of a number of factors: (i) the distinctness of the BARF1 binding site on CSF-1 away from the cognate receptor-binding sites, (ii) the species differences in human and mouse CSF-1R activation 20 and (iii) the evolutionary optimization of BARF1 to inactivate hCSF-1.
Finally, the identification of a new functional and modulatory hot spot centered at the intersubunit disulfide of CSF-1 has created profound implications for the 'druggability' and therapeutic targeting of the dimer interface region of CSF-1 and the homologous helical hematopoietic cytokines IL-34, stem-cell factor and Flt3 ligand. Efforts to antagonize RTK-III have predominantly focused on kinase-domain inhibition, an approach prone to poor specificity and development of resistance to treatment. In addition, the fortuitous picomolar affinity of mouse CSF-1 for BARF1 and its poor cross-reactivity with human CSF-1R 20 may render mouse CSF-1 an attractive starting point for the development of a BARF1 antagonist in vitro or in vivo. Likewise, BARF1 and BARF1 rhLCV could serve as lead protein-based therapeutics for the clinical targeting of the neutralization of CSF-1 mediated signaling.
METHODS
Methods and any associated references are available in the online version of the paper. Accession codes. Atomic coordinates and structure factors are deposited in the Protein Data Bank, with accession codes 3UEZ (BARF1-hCSF-1 complex to 3.4-Å resolution), 4ADF (BARF1-hCSF-1 complex to 4.4-Å resolution), 4ADQ (BARF1-mCSF-1 complex to 4.5-Å resolution), 3UF2 (hCSF-1 to 2.75-Å resolution), 3UF5 (mCSF-1 to 2.8-Å resolution).
